Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Aileron Therapeutics, Inc. on June 21, 2018. The company is an emerging growth company incorporated in Delaware. Note: The input metadata references "Rein Therapeutics, Inc.", but the filing text explicitly identifies the registrant as "Aileron Therapeutics, Inc."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
The primary material event reported is the outcome of the stockholder vote on director elections and auditor ratification.
Director Elections (Class I)
Three directors were elected for a three-year term ending in 2021. The voting results were as follows:
| Director Name | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Jeffrey A. Bailey | 8,647,744 | 53,347 | 4,339,742 |
| John H. McArthur, D.B.A. | 8,603,429 | 97,662 | 4,339,742 |
| Jodie P. Morrison | 8,594,065 | 107,026 | 4,339,742 |
Auditor Ratification
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
| Vote Type | Count |
|---|---|
| For | 12,999,486 |
| Against | 40,232 |
| Abstain | 1,115 |
| Broker Non-Votes | Not Applicable |
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the submission of matters to a vote of security holders.
Investor Verification Checklist
- Verify the company name discrepancy between the metadata (Rein Therapeutics) and the filing (Aileron Therapeutics).
- Confirm the total number of shares outstanding to contextualize the significant number of broker non-votes (4,339,742) relative to the "For" votes.
- Review the full proxy statement for details on the director nominees and the rationale for the auditor selection.
- Check subsequent filings for the company's financial performance, as this 8-K contains no financial data.